Result of AGM

RNS Number : 2078P
Tissue Regenix Group PLC
24 May 2018
 

Tissue Regenix Group plc

Result of AGM

Leeds, 24 May 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company provides notification that at the Group's AGM held earlier today, all resolutions were duly proposed to shareholders and passed.

 

For more Information:

 

Tissue Regenix Group plc

Caitlin Pearson                                 Head of Communications  

Tel: 0330 430 3073 / 07920272 441

 

 

Jefferies International Ltd

Simon Hardy / Christopher Binks  

Tel:  020 7029 8000

 

 

 

FTI Consulting 

Brett Pollard / Mo Noonan/ Mary Whittow

Tel: 0203 727 1000

 

 

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

 

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

 

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGSESFFLFASESI
UK 100

Latest directors dealings